Last updated: October 15, 2026
Relafen is the former U.S. branded product for nabumetone, a nonsteroidal anti-inflammatory drug approved for osteoarthritis and rheumatoid arthritis. Its commercial value shifted from branded prescription sales to low-margin generic volume after U.S. market exclusivity ended. Relafen has no meaningful remaining U.S. patent moat, and current financial exposure is concentrated in generic nabumetone rather than the original brand.
What is Relafen and how is it used?
Relafen contains nabumetone, a nonacidic NSAID prodrug. The FDA approved the product for relief of signs and symptoms associated with osteoarthritis and rheumatoid arthritis. Standard tablet strengths are 500 mg and 750 mg, with dosing commonly reaching 1,500 mg daily depending on clinical response and tolerability. [1]
Nabumetone is converted to its active metabolite, 6-methoxy-2-naphthylacetic acid. Like other NSAIDs, it carries boxed warnings for cardiovascular thrombotic events and gastrointestinal bleeding, ulceration and perforation. Renal toxicity, hypertension, fluid retention and hypersensitivity reactions are additional risks. [1]
| Attribute |
Relafen |
| Active ingredient |
Nabumetone |
| Drug class |
Nonsteroidal anti-inflammatory drug |
| Main indications |
Osteoarthritis and rheumatoid arthritis |
| U.S. dosage forms |
Oral tablets |
| Common strengths |
500 mg and 750 mg |
| U.S. reference sponsor |
SmithKline Beecham Pharmaceuticals |
| U.S. NDA |
19-583 |
| Initial FDA approval |
1991 |
| Current commercial status |
Generic-dominated |
| Biosimilar relevance |
None; Relafen is a small-molecule drug |
When did Relafen lose exclusivity?
Relafen lost its commercial exclusivity after the expiration of the original patent and regulatory exclusivity periods. FDA records identify nabumetone as an established generic active ingredient, with multiple approved abbreviated new drug applications. [2]
The original branded product benefited from the normal early-life advantages of a new prescription NSAID, including physician familiarity, sales promotion and protected market positioning. Those advantages diminished after generic nabumetone entered the U.S. market.
U.S. exclusivity timeline
| Period |
Commercial event |
Market effect |
| 1991 |
FDA approval of Relafen |
Branded product begins U.S. commercialization |
| 1990s |
Brand expansion in arthritis treatment |
Relafen competes with established NSAIDs |
| Early 2000s |
Generic nabumetone approvals and market entry |
Payer substitution accelerates |
| Later 2000s |
Brand and generic coexistence |
Relafen loses formulary preference |
| 2010s onward |
Generic-dominated market |
Brand value declines sharply |
| Current market |
Nabumetone supplied mainly by generic manufacturers |
Low unit prices and limited differentiation |
The precise commercial inflection point varied by dosage strength, manufacturer and litigation outcome. The strategic conclusion is clear: Relafen is a post-exclusivity product, not an active branded-growth asset.
What patents protected Relafen?
Relafen's original patent estate protected nabumetone as a chemical entity and pharmaceutical product. Those rights are now expired or commercially exhausted in the United States. Current generic nabumetone products are not dependent on a live Relafen patent position for routine market access.
The historical estate likely included compound, formulation and use-related claims associated with the original development program. Those claims do not create a current barrier to generic substitution. The relevant U.S. protection categories are summarized below.
| Protection category |
Historical relevance |
Current commercial effect |
| Active-ingredient or compound claims |
Protected nabumetone development |
Expired or no longer commercially blocking |
| Tablet formulation claims |
Covered oral dosage presentation |
No material barrier to standard generics |
| Method-of-use claims |
Related to arthritis treatment |
Broad indication claims no longer protect brand economics |
| Manufacturing claims |
May have covered synthesis or process controls |
Alternative generic processes reduce practical impact |
| Pediatric exclusivity |
No material current relevance |
Expired |
| Regulatory exclusivity |
Applied only during the initial launch period |
Expired |
What is the Orange Book status of Relafen?
Relafen was approved under NDA 19-583. The FDA Orange Book is the principal U.S. source for listed drugs, therapeutic equivalence codes and patent or exclusivity information. [2]
For current commercial analysis, the important point is that nabumetone is available through abbreviated new drug applications and therapeutic-equivalence pathways. A generic product rated therapeutically equivalent to the reference listed drug can normally be substituted under state pharmacy laws, subject to local substitution rules and payer requirements.
The Orange Book does not create an ongoing commercial moat for the Relafen brand. Any historical patent listings have expired, been delisted, or lost practical significance because of the age of the product.
Which companies manufacture generic nabumetone?
Generic nabumetone has been supplied by multiple U.S. manufacturers over time. Manufacturer participation can change because of product discontinuations, facility decisions, acquisitions and FDA supply conditions. The competitive field has included large generic companies and smaller contract or specialty suppliers.
Examples of companies associated with nabumetone generic filings or supply over time include:
- Teva Pharmaceuticals
- Zydus Pharmaceuticals
- Rising Pharma
- Solco Healthcare
- Other FDA-approved generic applicants and private-label distributors
The commercial market is fragmented at the product level but highly concentrated in purchasing. Pharmacies and health plans generally prioritize the lowest-cost therapeutically equivalent source, reliable supply and rebate terms.
How strong is the Relafen patent estate?
The current patent strength is effectively weak for U.S. branded-product purposes.
Relafen has four structural disadvantages:
- The active ingredient is old and widely understood.
- Generic manufacturers have had extensive time to develop alternative suppliers and manufacturing routes.
- The principal indications are broad and clinically established.
- Oral tablets are difficult to protect with durable formulation differentiation unless a new delivery technology is introduced.
A new patent directed to a narrow formulation, manufacturing process or combination therapy would not restore the historical Relafen franchise without a commercially meaningful product change. It would also face validity, written-description, enablement and obviousness risks typical of late-life reformulation patents.
Are there Paragraph IV challenges to Relafen?
Paragraph IV litigation is no longer a central market issue for Relafen. Paragraph IV certifications are used when a generic applicant asserts that a listed patent is invalid, unenforceable or will not be infringed. [3]
The major commercial phase for such challenges would have occurred before or around generic entry. Because Relafen's core exclusivity has expired, a new Paragraph IV campaign would have limited strategic value unless a new, enforceable patent were listed against a specific branded formulation.
The practical generic-launch risk is therefore low in legal terms but high in commercial terms for any attempt to revive the brand. Generic manufacturers already possess the relevant market pathway.
What formulation patents protect nabumetone products?
Standard nabumetone tablets have limited differentiation. The primary commercial product is an immediate-release oral tablet. A formulation patent could theoretically address:
- Modified release
- Gastrointestinal tolerability
- Dose reduction
- Improved bioavailability
- Combination therapy
- Patient-specific delivery
- Alternative tablet coatings or excipients
No such formulation category currently creates a known, durable market barrier around conventional Relafen tablets. A modified-release or combination product would require a separate clinical, regulatory and reimbursement strategy. It would compete with established NSAIDs and newer approaches to chronic pain management.
What is the FDA regulatory status of Relafen?
Relafen is an approved prescription NSAID product. Generic nabumetone products are approved through the ANDA pathway, which generally relies on pharmaceutical equivalence and bioequivalence rather than a new efficacy trial. [1, 2]
The FDA label identifies major safety restrictions:
- Serious cardiovascular events can occur with NSAID use.
- Gastrointestinal bleeding and ulceration may occur without warning.
- NSAIDs can impair renal function.
- Use around coronary artery bypass graft surgery is contraindicated.
- Nabumetone is contraindicated in patients with prior serious hypersensitivity reactions to aspirin or NSAIDs.
- NSAID use during pregnancy is restricted, particularly late in gestation.
These warnings constrain chronic-use expansion and increase the importance of physician selection, patient monitoring and payer preference.
How does Relafen compare with competing NSAIDs?
Relafen competes in a mature, price-sensitive NSAID market. Its clinical positioning depends less on novelty than on prescriber familiarity, tolerability perceptions, dosing convenience and generic price.
| Drug |
Active ingredient |
Main commercial strength |
Main competitive limitation |
| Relafen |
Nabumetone |
Established oral NSAID with generic availability |
Limited differentiation |
| Naprosyn |
Naproxen |
Broad physician familiarity and low generic cost |
NSAID cardiovascular and GI risks |
| Mobic |
Meloxicam |
Once-daily dosing and broad generic use |
Generic erosion |
| Voltaren |
Diclofenac |
Multiple dosage forms and topical options |
Cardiovascular and hepatic concerns |
| Celebrex |
Celecoxib |
COX-2 selectivity and brand recognition |
Higher cost than many traditional NSAIDs |
| Ibuprofen |
Ibuprofen |
Very low cost and over-the-counter access |
Shorter dosing interval and class risks |
Nabumetone's nonacidic prodrug design historically supported a tolerability narrative. That positioning is insufficient to sustain brand pricing when low-cost alternatives are available and clinical guidelines emphasize individualized NSAID selection.
What is the financial trajectory for Relafen?
Relafen's financial trajectory follows the standard lifecycle of an older small-molecule medicine:
- Initial branded growth after FDA approval.
- Mature branded sales as arthritis prescribing expands.
- Revenue compression after generic entry.
- Rapid erosion of branded volume and price.
- Residual sales through limited brand prescriptions, institutional demand or legacy prescribing.
- Generic-market stabilization at low unit prices.
Public company disclosures generally do not provide a current standalone Relafen revenue line. The product was part of broader prescription portfolios, and later generic sales are distributed across several manufacturers. Consequently, a precise current Relafen revenue figure is not publicly established in FDA records or standard issuer reporting.
The financial exposure is now better measured through prescription volume, average selling price and manufacturer participation than through brand revenue. Generic nabumetone can retain stable unit demand while producing limited manufacturer profit because:
- Several suppliers compete for formulary access.
- Pharmacy benefit managers negotiate aggressively.
- The active ingredient is mature.
- Tablet manufacturing is relatively conventional.
- Substitution limits brand loyalty.
- Inventory and regulatory compliance costs absorb a greater share of gross margin at low prices.
What generic entry risks exist for a Relafen relaunch?
A branded relaunch would face immediate generic substitution unless it introduced a distinct FDA-approved product with enforceable intellectual property. The main risks would include:
- Therapeutically equivalent nabumetone substitution
- Low reimbursement for an unpreferred brand
- Pharmacy-level substitution
- Limited physician incentive to prescribe a premium product
- Payer preference for naproxen, meloxicam or diclofenac
- Difficulty obtaining durable patent claims
- Weak return on promotional spending
A relaunch could be viable only under a differentiated model, such as a novel delivery system, a fixed-dose combination, a prescription-to-specialty repositioning or a clinically validated tolerability advantage. Even then, regulatory and reimbursement costs would be substantial.
Does Relafen have biosimilar risk?
Relafen has no biosimilar risk because nabumetone is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic substitution through ANDA approvals, not the abbreviated biologics license application pathway used for biosimilars.
What licensing deals affect Relafen?
No major current licensing transaction is publicly associated with Relafen's commercial value. The product's original rights were tied to the branded pharmaceutical portfolio of its historical sponsor. After generic erosion, licensing economics became limited because the active ingredient was broadly available and the brand lacked a defensible premium.
A transaction involving nabumetone today would likely concern manufacturing rights, regional distribution or a reformulated product rather than the legacy Relafen brand.
What patent litigation affects Relafen?
Historical generic-entry litigation may have involved challenges to patents associated with nabumetone or the branded product. Those disputes no longer determine current U.S. access because generic nabumetone is established in the market.
The litigation risk for a new Relafen-related product would instead concern:
- New formulation patents
- Orange Book listing strategy
- Paragraph IV challenges
- Patent-term restoration or extension eligibility
- Therapeutic-equivalence disputes
- State substitution and labeling issues
The legacy product does not present an active litigation-driven barrier to generic competition.
What is the geographic coverage of Relafen protection?
Relafen's strongest historical commercial position was in the United States, where FDA approval, Orange Book listing and U.S. patent rights shaped market access. Patent terms and generic pathways vary by jurisdiction.
In Europe, national and centralized regulatory systems, national patent rights and local generic substitution rules determine access. In emerging markets, nabumetone availability depends on local registration, procurement and manufacturer economics. The global brand has limited strategic value because generic NSAIDs are widely available and local price competition is strong.
Key Takeaways
- Relafen is the former branded nabumetone product for osteoarthritis and rheumatoid arthritis.
- FDA approval dates to 1991, and U.S. exclusivity has long expired.
- Generic nabumetone, not Relafen, represents the active commercial market.
- The current U.S. patent estate provides no meaningful barrier to routine generic competition.
- Paragraph IV risk is largely historical; substitution and price competition are the current threats.
- Relafen has no biosimilar exposure because nabumetone is a small molecule.
- Standalone current Relafen revenue is not publicly reported.
- Any commercial revival would require a differentiated formulation, delivery system or combination product with new intellectual-property protection.
- The financial profile is low-margin, mature and volume-driven.
FAQs
Is Relafen still prescribed?
Relafen as a brand has limited commercial relevance, but nabumetone remains available as a generic prescription NSAID.
Is nabumetone stronger than ibuprofen?
Clinical response varies by patient. Nabumetone is not categorically stronger than ibuprofen, and treatment selection depends on efficacy, dosing, comorbidities and NSAID safety risks.
Can pharmacies automatically substitute generic nabumetone for Relafen?
In many U.S. jurisdictions, therapeutically equivalent generic nabumetone can be substituted under state pharmacy rules unless the prescriber or patient restricts substitution.
Is nabumetone safer for the stomach than other NSAIDs?
Nabumetone was developed with a nonacidic prodrug design, but it still carries the class risk of gastrointestinal bleeding, ulceration and perforation. It should not be treated as risk-free.
Could a new Relafen formulation regain market exclusivity?
A new formulation could potentially receive patent protection and separate regulatory approval, but commercial success would depend on clinical differentiation, enforceable claims, reimbursement and the ability to avoid generic substitution.
References
-
U.S. Food and Drug Administration. (2023). Relafen (nabumetone) tablets: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and paragraph IV certifications. FDA.
